Diabetes, weight loss drug companies growth far from over, says ClearBridge analyst

ClearBridge research analyst Marshall Gordon sits down with InvestmentNews anchor Gregg Greenberg to discuss the rise of new diabetes and weight-loss drugs, as well as the best ways to invest in this burgeoning sector.
  • Aug 30, 2023
More: IN THE NASDAQ
Here's what to expect from REITs in the second half of 2025

Here's what to expect from REITs in the second half of 2025

International stock outperformance not finished yet

International stock outperformance not finished yet

Why the 'great global realignment' will boost foreign small-cap stocks

Why the 'great global realignment' will boost foreign small-cap stocks